<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116007</url>
  </required_header>
  <id_info>
    <org_study_id>AK112-103</org_study_id>
    <nct_id>NCT05116007</nct_id>
  </id_info>
  <brief_title>Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC</brief_title>
  <official_title>Phase Ib Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Etoposide and Carboplatin for the First-line Treatment of Patients With Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase Ib open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and&#xD;
      VEGF bispecific antibody (AK112) combined with chemotherapy in patients with ES-SCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Grade 3 or higher adverse events (AEs)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 years]</time_frame>
    <description>ORR is the proportion of subjects with CR or PR , based on RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to approximately 2 years]</time_frame>
    <description>DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for â‰¥8 weeks) based on RECIST V1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to approximately 2 years]</time_frame>
    <description>PFS is defined as the time from the date of first dosing till the first documentation of disease progression (per RECIST v1.1) assessed by the investigator or death due to any cause (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 2 years]</time_frame>
    <description>OS is the time from the date of randomization or first dosing date to death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>SCLC, Extensive Stage</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive AK112 plus Etoposide and Carboplatin every 3- week cycle (Q3W) for 4 cycles followed by AK112 until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK112</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 75 years old (at the time of inform consent obtained).&#xD;
&#xD;
          -  Be able and willing to provide written informed consent and to comply with all&#xD;
             requirements of study participation (including all study procedures).&#xD;
&#xD;
          -  Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration&#xD;
             Lung Study Group [VALG] staging system).&#xD;
&#xD;
          -  Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue obtained from&#xD;
             either a core or excisional tumor biopsy.&#xD;
&#xD;
          -  Have a life expectancy of at least 3 months.&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             1.1 assessed by investigator&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
          -  All female and male subjects of reproductive potential must agree to use an effective&#xD;
             method of contraception, as determined by the Investigator, during and for 120 days&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undergone major surgery within 30 days prior to the first dose of study treatment&#xD;
&#xD;
          -  History of prior malignancy except that basal cell carcinoma of the skin, squamous&#xD;
             cell carcinoma of the skin that has undergone potentially curative therapy or in situ&#xD;
             cervical cancer&#xD;
&#xD;
          -  Active central nervous system (CNS) metastases&#xD;
&#xD;
          -  History of active autoimmune disease that has required systemic treatment in the past&#xD;
             2 years (i.e.,corticosteroids or immunosuppressive drugs).&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Active Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina, cardiac or other vascular stenting,&#xD;
             angioplasty, or surgery within 12 months prior to day 1 of study treatment;&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weifeng Song, MD</last_name>
    <phone>+86(0760)89873999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shun Lu</last_name>
    <phone>+8621-62821990</phone>
    <email>shun_lu@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shun Lu</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Lu</last_name>
      <phone>+862162821990</phone>
      <email>shun_lu@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

